Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal®, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France). Alustal® will be also available in Australia, France and Switzerland in the coming months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005500/en/
“We are pleased that patients and the medical community have access to an alternative allergen immunotherapy option with Alustal®. Stallergenes Greer’s comprehensive SCIT offering is the result of sustained investments in state-of-the-art manufacturing facilities and quality systems and reflects our commitment to offer a wide range of personalised treatment options which meet physicians’ needs for precision treatment” declares Amer Jaber, Executive VP Operations Europe & International.
Stallergenes Greer’s SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician. The company’s SCIT offering also includes Albey® which will be progressively reintroduced and Alyostal® prick tests.
Stallergenes Greer is committed to developing a wide portfolio of precise personalised treatment solutions tailored to each patient profile and to each market, including diagnostics, injectable therapies and sublingual therapies such as drops and tablets.
ABOUT ALUSTAL®
Alustal® is an aluminium-based suspension for subcutaneous injection launched in 1997.The aluminum adjuvant allows the slow release of antigen at the injection site to stimulate the immune response.
Alustal® is indicated for Type I allergies (Gell and Coombs classification) mainly involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate), of a seasonal or perennial nature, in children, adolescents and adults.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005500/en/
Contact information
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owlet ® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark30.10.2025 14:45:00 EET | Press release
Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that its newest video monitoring device, Dream Sight, is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. Dream Sight was tested by Brightsight, an SGS company and global leader in cybersecurity evaluations. For parents, this independent recognition provides extra reassurance that Owlet delivers trusted digital solutions backed by strong encryption, secure data management, and advanced privacy safeguards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106669800/en/ Owlet's Dream Sight is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. “Earning the SGS Cybersecurity Mark un
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory30.10.2025 14:30:00 EET | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks the company’s second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to expanding its global network of compliant, clinical-grade laboratories. Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability, and quality. The designation affirms that Crown Bioscience’s Suzhou laboratory meets all required compliance benchmarks, providing clients with greater confidence in the biomarker data that supports their clinical development and regulatory submissions. ‘’Earning a second CLIA certification within
2025 Ecolab Watermark ™ Study Reveals Hidden Impact of Artificial Intelligence30.10.2025 14:30:00 EET | Press release
Ecolab, a global sustainability leader offering water solutions and services, today announced findings from its third annual Ecolab Watermark™ Study, which reports on water stewardship around the world. This year’s research highlights water’s connection to timely global trends, including new business opportunities from the rapid growth of artificial intelligence (AI) and consumer concern about its impact on vital natural resources. According to the Watermark Study, a majority of consumers across fifteen countries understand the power demands of AI, but far fewer recognize the hidden impact of AI – the amount of water required to manufacture AI technology and operate data centers. In the United States (U.S.), just 46% of consumers acknowledge the use of water in AI operations compared to 55% recognizing the use of power. In other regions, including Asia Pacific and Latin America, the gap is even more pronounced. “By 2050, the world will have nearly 30% more people and require 47% more e
SLB OneSubsea Secures EPC Contracts from PTTEP for Two Deepwater Projects Offshore Malaysia30.10.2025 14:30:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) announced today the award of two sizeable engineering, procurement, and construction (EPC) contracts by PTT Exploration and Production Public Company Limited (PTTEP) to its OneSubsea™ joint venture. The contracts build on a 20-year collaboration between the two companies and cover the expansion of two fields offshore Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030090404/en/ As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. The scope includes hor
Novotech Maps Global Growth in Radiopharmaceutical Trials30.10.2025 14:05:00 EET | Press release
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, today released a new white paper detailing the rapid rise of therapeutic radiopharmaceutical research and the operational frameworks needed to support these complex studies at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030722919/en/ The analysis shows that global therapeutic radiopharmaceutical trials have grown from just a handful in 2018 to more than 80 active studies by August 2025, a tenfold increase highlighting the growth in this advancing area of precision oncology. Therapeutic radiopharmaceuticals deliver targeted radiation directly to tumors via beta and alpha emitters, minimizing off-target exposure. The white paper highlights the clinical role of beta emitters such as Lutetium-177, the growing interest in targeted alpha therapy (TAT), and the critical supply-chain challenges posed by short-lived isotopes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom